Aclaris Therapeutics (ACRS) Competitors $1.91 -0.04 (-2.05%) Closing price 09/19/2025 04:00 PM EasternExtended Trading$1.88 -0.03 (-1.57%) As of 09/19/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ACRS vs. PHAT, TSHA, IOVA, AVXL, IMNM, AVBP, PRAX, GOSS, AKBA, and VALNShould you be buying Aclaris Therapeutics stock or one of its competitors? The main competitors of Aclaris Therapeutics include Phathom Pharmaceuticals (PHAT), Taysha Gene Therapies (TSHA), Iovance Biotherapeutics (IOVA), Anavex Life Sciences (AVXL), Immunome (IMNM), ArriVent BioPharma (AVBP), Praxis Precision Medicines (PRAX), Gossamer Bio (GOSS), Akebia Therapeutics (AKBA), and Valneva (VALN). These companies are all part of the "pharmaceutical products" industry. Aclaris Therapeutics vs. Its Competitors Phathom Pharmaceuticals Taysha Gene Therapies Iovance Biotherapeutics Anavex Life Sciences Immunome ArriVent BioPharma Praxis Precision Medicines Gossamer Bio Akebia Therapeutics Valneva Phathom Pharmaceuticals (NASDAQ:PHAT) and Aclaris Therapeutics (NASDAQ:ACRS) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, media sentiment, profitability, earnings and risk. Is PHAT or ACRS more profitable? Phathom Pharmaceuticals has a net margin of -289.51% compared to Aclaris Therapeutics' net margin of -802.03%. Phathom Pharmaceuticals' return on equity of 0.00% beat Aclaris Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Phathom Pharmaceuticals-289.51% N/A -90.40% Aclaris Therapeutics -802.03%-34.01%-24.18% Which has better valuation and earnings, PHAT or ACRS? Aclaris Therapeutics has lower revenue, but higher earnings than Phathom Pharmaceuticals. Phathom Pharmaceuticals is trading at a lower price-to-earnings ratio than Aclaris Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPhathom Pharmaceuticals$55.25M14.39-$334.33M-$4.73-2.37Aclaris Therapeutics$18.72M11.05-$132.07M-$1.37-1.39 Do institutionals and insiders have more ownership in PHAT or ACRS? 99.0% of Phathom Pharmaceuticals shares are held by institutional investors. Comparatively, 98.3% of Aclaris Therapeutics shares are held by institutional investors. 24.1% of Phathom Pharmaceuticals shares are held by company insiders. Comparatively, 5.6% of Aclaris Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Which has more risk and volatility, PHAT or ACRS? Phathom Pharmaceuticals has a beta of 0.44, indicating that its share price is 56% less volatile than the S&P 500. Comparatively, Aclaris Therapeutics has a beta of 0.27, indicating that its share price is 73% less volatile than the S&P 500. Do analysts rate PHAT or ACRS? Phathom Pharmaceuticals presently has a consensus price target of $17.50, indicating a potential upside of 56.11%. Aclaris Therapeutics has a consensus price target of $8.71, indicating a potential upside of 356.25%. Given Aclaris Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Aclaris Therapeutics is more favorable than Phathom Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Phathom Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.00Aclaris Therapeutics 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.11 Does the media refer more to PHAT or ACRS? In the previous week, Aclaris Therapeutics had 1 more articles in the media than Phathom Pharmaceuticals. MarketBeat recorded 4 mentions for Aclaris Therapeutics and 3 mentions for Phathom Pharmaceuticals. Aclaris Therapeutics' average media sentiment score of 1.18 beat Phathom Pharmaceuticals' score of 0.56 indicating that Aclaris Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Phathom Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aclaris Therapeutics 2 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryAclaris Therapeutics beats Phathom Pharmaceuticals on 9 of the 16 factors compared between the two stocks. Get Aclaris Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ACRS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ACRS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ACRS vs. The Competition Export to ExcelMetricAclaris TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$206.91M$2.57B$5.80B$10.47BDividend YieldN/A55.05%5.61%4.57%P/E Ratio-1.3922.8180.4926.84Price / Sales11.05707.99536.46125.70Price / CashN/A27.8326.0131.15Price / Book1.335.2915.776.42Net Income-$132.07M$32.95M$3.30B$271.73M7 Day Performance-2.05%0.90%5.35%3.51%1 Month Performance9.14%4.71%7.28%9.59%1 Year Performance66.09%-2.98%80.88%28.60% Aclaris Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ACRSAclaris Therapeutics3.1704 of 5 stars$1.91-2.1%$8.71+356.2%+66.1%$206.91M$18.72M-1.39100News CoveragePositive NewsHigh Trading VolumePHATPhathom Pharmaceuticals2.4748 of 5 stars$11.48-3.0%$17.50+52.4%-39.2%$839.97M$55.25M-2.43110TSHATaysha Gene Therapies2.1895 of 5 stars$3.02-1.6%$8.29+174.4%+31.6%$837.48M$8.33M-8.88180Positive NewsIOVAIovance Biotherapeutics4.2867 of 5 stars$2.27flat$11.90+424.2%-79.8%$821.41M$164.07M-1.85500AVXLAnavex Life Sciences3.8451 of 5 stars$9.09-3.0%$44.00+384.0%+50.0%$804.83MN/A-15.9540IMNMImmunome2.193 of 5 stars$9.48+2.9%$22.89+141.4%-37.4%$801.68M$9.04M-3.0840News CoverageAnalyst ForecastAVBPArriVent BioPharma2.0487 of 5 stars$18.95-3.9%$39.14+106.6%-28.9%$799.61MN/A-4.7140PRAXPraxis Precision Medicines2.4004 of 5 stars$40.45+7.3%$85.88+112.3%-31.4%$793.67M$8.55M-3.29110Positive NewsAnalyst ForecastGOSSGossamer Bio3.9655 of 5 stars$3.18-8.1%$8.50+167.3%+190.5%$786.74M$114.70M-5.13180Positive NewsAnalyst DowngradeAKBAAkebia Therapeutics3.7506 of 5 stars$2.92-1.0%$6.75+131.2%+105.8%$782.18M$160.18M-17.18430Positive NewsVALNValneva2.6288 of 5 stars$8.93-0.1%$15.00+68.0%+73.1%$768.19M$183.52M-9.11700Gap Up Related Companies and Tools Related Companies Phathom Pharmaceuticals Competitors Taysha Gene Therapies Competitors Iovance Biotherapeutics Competitors Anavex Life Sciences Competitors Immunome Competitors ArriVent BioPharma Competitors Praxis Precision Medicines Competitors Gossamer Bio Competitors Akebia Therapeutics Competitors Valneva Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ACRS) was last updated on 9/21/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aclaris Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aclaris Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
